Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATRA

ATRA - Atara Biotherapeutics Inc Stock Price, Fair Value and News

0.79USD-0.01 (-1.25%)Market Closed
Watchlist

Market Summary

USD0.79-0.01
Market Closed
-1.25%

ATRA Alerts

  • GOLDMAN SACHS GROUP INC reported owning 0.6% of ATRA [2024-02-06]

ATRA Stock Price

View Fullscreen

ATRA RSI Chart

ATRA Valuation

Market Cap

80.5M

Price/Earnings (Trailing)

-0.28

Price/Sales (Trailing)

1.23

EV/EBITDA

-0.06

Price/Free Cashflow

-0.4

ATRA Price/Sales (Trailing)

ATRA Profitability

EBT Margin

-456.55%

Return on Equity

-15.62%

Return on Assets

-153.74%

Free Cashflow Yield

-249.22%

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

63.6M

Rev. Growth (Yr)

-52.05%

Rev. Growth (Qtr)

123.41%

ATRA Earnings

Earnings (TTM)

-290.2M

Earnings Growth (Yr)

17%

Earnings Growth (Qtr)

1.84%

Breaking Down ATRA Revenue

Last 7 days

-6.1%

Last 30 days

6.9%

Last 90 days

51.0%

Trailing 12 Months

-81.9%

How does ATRA drawdown profile look like?

ATRA Financial Health

Current Ratio

1.5

ATRA Investor Care

Shares Dilution (1Y)

7.42%

Diluted EPS (TTM)

-2.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202224.1M71.8M70.9M63.6M
202100020.3M
20200000
20190000
20180000
20170000
20160000
2015272.0K412.0K762.0K0
201440.3K68.5K96.8K125.0K
201300012.0K

Tracking the Latest Insider Buys and Sells of Atara Biotherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 08, 2024
henrich jill
acquired
-
-
450,000
evp, global head ra & quality
Jan 08, 2024
hyllengren eric j
acquired
-
-
475,000
evp, cfo
Jan 08, 2024
nguyen anhco
acquired
-
-
675,000
evp, chief sci. & tech officer
Jan 08, 2024
touchon pascal
acquired
-
-
1,280,000
president and ceo
Jan 08, 2024
murugan amar
acquired
-
-
475,000
evp, chief legal officer
Nov 16, 2023
murugan amar
sold
-3,231
0.389
-8,307
evp, chief legal officer
Nov 16, 2023
nguyen anhco
sold
-3,444
0.389
-8,856
evp, chief sci. & tech officer
Nov 16, 2023
henrich jill
sold
-1,270
0.389
-3,267
evp, global head ra & quality
Nov 16, 2023
touchon pascal
sold
-7,939
0.389
-20,409
president and ceo
Nov 16, 2023
joshi manher
sold
-4,779
0.389
-12,287
evp, chief medical officer

1–10 of 50

Which funds bought or sold ATRA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
402,000
402,000
0.03%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-53,000
29,000
-%
Feb 15, 2024
WEXFORD CAPITAL LP
new
-
15,353
15,353
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
1.00
1.00
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
464
33,142
67,780
-%
Feb 15, 2024
BARCLAYS PLC
added
693
44,000
69,000
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-8,749
4,640
-%
Feb 14, 2024
Metropolitan Life Insurance Co/NY
sold off
-100
-7,640
-
-%
Feb 14, 2024
STATE STREET CORP
added
10.37
-2,305,840
1,427,740
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
added
119
-22,778
72,077
-%

1–10 of 45

Are Funds Buying or Selling ATRA?

Are funds buying ATRA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATRA
No. of Funds

Unveiling Atara Biotherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
maverick capital ltd
0%
0
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
10,301,409
SC 13G/A
Feb 13, 2024
vanguard group inc
6.56%
6,686,043
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 06, 2024
goldman sachs group inc
0.6%
580,629
SC 13G/A
Jan 26, 2024
blackrock inc.
7.0%
7,087,213
SC 13G/A
Jan 22, 2024
state street corp
2.73%
2,784,200
SC 13G/A
Jan 09, 2024
baupost group llc/ma
0%
0
SC 13G/A
Dec 07, 2023
jpmorgan chase & co
2.1%
2,206,929
SC 13G/A
Nov 21, 2023
ecor1 capital, llc
9.9%
10,067,043
SC 13G

Recent SEC filings of Atara Biotherapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
SC 13G/A
Major Ownership Report
Jan 09, 2024
SC 13G/A
Major Ownership Report
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading

Peers (Alternatives to Atara Biotherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Atara Biotherapeutics Inc News

Latest updates
Yahoo Finance03 Feb 202408:00 am
Simply Wall St02 Feb 202408:00 am

Atara Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue123.4%2,138,000957,000589,000221,0004,459,00051,579,0007,314,0007,548,0005,370,0003,870,0003,552,000----------
Costs and Expenses-71,750,000---89,081,000----------------
Operating Expenses-100.0%-72,371,00076,244,00075,760,00089,081,00083,711,00095,534,000100,951,00090,182,00087,872,00081,797,000----------
  S&GA Expenses-8.2%12,247,00013,335,00013,872,00013,245,00018,924,00018,813,00020,571,00021,817,00019,849,00019,397,00017,738,000----------
  R&D Expenses1.3%56,888,00056,141,00062,156,00062,515,00070,157,00064,898,00074,963,00079,134,00070,333,00068,475,00064,059,000----------
EBITDA Margin5.2%-4.42-4.66-3.27-3.50-3.38-3.34-14.15-16.26-418-405-397-391---------
Interest Expenses1.2%1,395,0001,378,0001,336,00079,000123,000129,0004,0007,0007,0008,00010,000----------
Income Taxes-2000.0%-19,0001,00022,0002,00010,000--30,000-16,000-----------
Earnings Before Taxes1.8%-69,816,000-71,107,000-74,749,000-74,570,000-84,081,00018,466,000-88,105,000-93,319,000-84,664,000-83,777,000-78,335,000----------
EBT Margin4.7%-4.57-4.79-3.38-3.59-3.48-3.45-14.52-16.72-430-417-408-402---------
Net Income1.8%-69,797,000-71,108,000-74,771,000-74,572,000-84,091,00018,466,000-88,105,000-93,349,000-84,664,000-83,793,000-78,335,000----------
Net Income Margin4.7%-4.57-4.79-3.38-3.59-3.48-3.45-14.52-16.72-430-417-408-402---------
Free Cashflow3.1%-51,627,000-53,295,000-38,828,000-56,917,000-65,189,000-65,383,000-87,134,000-36,735,000-62,834,000-63,638,000-67,895,000-4,721,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-23.4%189246302376368436397468450457530588406428300343365274325392443
  Current Assets-31.1%119172224295283347314385369392464523339359229273293201251321373
    Cash Equivalents41.2%65.0046.0049.0093.0066.0072.0010310711512515220264.0076.0072.0076.0096.0061.0058.0062.0067.00
  Inventory-16.2%7.008.005.002.00-----------------
  Net PPE-13.5%5.005.006.006.007.008.009.0054.0053.0051.0051.0051.0052.0054.0054.0054.0056.0057.0058.0069.0068.00
Liabilities0.3%24023923725018117917318914012513112652.0047.0047.0052.0046.0042.0041.0053.0040.00
  Current Liabilities6.1%79.0075.0068.0079.0072.0066.0010210686.0089.0084.0083.0036.0032.0032.0037.0031.0026.0025.0040.0027.00
Shareholder's Equity24831.9%1,8587.0065.00127187257224280310332399462354381253291318232284339403
  Retained Earnings-3.8%-1,908-1,838-1,767-1,693-1,618-1,534-1,552-1,464-1,371-1,286-1,202-1,124-1,043-968-891-817-739-667-593-527-447
  Additional Paid-In Capital0.6%1,8581,8471,8341,8221,8091,7941,7791,7451,6811,6181,6021,5871,3971,3491,1441,1091,058900877867851
Shares Outstanding0.8%10210197.0096.0010210210192.0092.0092.0091.0074.00---------
Float------715---1,150---907---761---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations2.7%-51,346-52,796-38,429-56,880-65,057-63,964-84,529-34,269-58,978-61,577-65,698-4,120-52,959-56,636-67,044-58,690-52,147-54,589-70,200-57,419-48,097
  Share Based Compensation-11.2%11,14312,55211,76411,36314,02314,11714,33514,02813,76213,80712,26811,50413,25513,94812,64412,07412,15215,20112,2699,5539,251
Cashflow From Investing42.4%70,44749,482-6,00751,21859,69731,82660,215-24,3241,19431,88913,499-36,8927,562-130,37138,9731,127-58,51750,25367,59646,06811,437
Cashflow From Financing-144.2%-20847123532,290-2141,15719,85151,46847,1372,4472,892178,79633,506191,31523,95737,449145,9367,327-1,9266,021-515

ATRA Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Commercialization revenue$ 2,020$ 0$ 3,697$ 0
License and collaboration revenue1184,45962463,352
Total revenue2,1384,4594,32163,352
Costs and operating expenses:    
Cost of commercialization revenue2,61505,7260
Research and development expenses56,88870,157175,185210,018
General and administrative expenses12,24718,92439,45458,308
Total costs and operating expenses71,75089,081220,365268,326
Loss from operations(69,612)(84,622)(216,044)(204,974)
Other income (expense), net:    
Interest income1,2189734,7151,904
Interest expense(1,395)(123)(4,109)(256)
Gain on sale of ATOM Facility00050,237
Other income (expense), net(27)(309)(234)(631)
Total other income (expense), net20454137251,254
Loss before provision for (benefit from) income taxes(69,816)(84,081)(215,672)(153,720)
Provision for (benefit from) income taxes(19)10410
Net loss(69,797)(84,091)(215,676)(153,730)
Other comprehensive gain (loss):    
Unrealized gain (loss) on available-for-sale securities362(341)1,496(2,591)
Comprehensive loss$ (69,435)$ (84,432)$ (214,180)$ (156,321)
Basic loss per common share$ (0.66)$ (0.82)$ (2.05)$ (1.51)
Diluted loss per common share$ (0.66)$ (0.82)$ (2.05)$ (1.51)
Basic weighted-average shares outstanding106,401102,423105,163101,590
Diluted weighted-average shares outstanding106,401102,423105,163101,590

ATRA Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 64,791$ 92,942
Short-term investments37,617149,877
Restricted cash146146
Accounts receivable16340,221
Inventories6,5911,586
Other current assets9,38810,308
Total current assets118,696295,080
Property and equipment, net4,6286,300
Operating lease assets59,17568,022
Other assets6,2897,018
Total assets188,788376,420
Current liabilities:  
Accounts payable6,5116,871
Accrued compensation14,43017,659
Accrued research and development expenses23,96824,992
Deferred revenue11,6118,000
Other current liabilities22,56921,394
Total current liabilities79,08978,916
Deferred revenue - long-term73,92977,000
Operating lease liabilities - long-term48,50858,064
Liability related to the sale of future revenues - long-term33,25230,236
Other long-term liabilities4,8485,564
Total liabilities239,626249,780
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):  
Common stock - $0.0001 par value, 500,000 shares authorized as of September 30, 2023 and December 31, 2022; 101,922 and 95,927 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively1010
Additional paid-in capital1,858,4231,821,721
Accumulated other comprehensive (loss) income(571)(2,067)
Accumulated deficit(1,908,700)(1,693,024)
Total stockholders' equity (deficit)(50,838)126,640
Total liabilities and stockholders' equity (deficit)$ 188,788$ 376,420
ATRA
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
 CEO
 WEBSITEwww.atarabio.com
 EMPLOYEES317

Atara Biotherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Atara Biotherapeutics Inc? What does ATRA stand for in stocks?

ATRA is the stock ticker symbol of Atara Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atara Biotherapeutics Inc (ATRA)?

As of Thu Feb 22 2024, market cap of Atara Biotherapeutics Inc is 80.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers. The fair value of Atara Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atara Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atara Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATRA is over valued or under valued. Whether Atara Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Atara Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRA.

What is Atara Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ATRA's PE ratio (Price to Earnings) is -0.28 and Price to Sales (PS) ratio is 1.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRA PE ratio will change depending on the future growth rate expectations of investors.